Misha V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical
University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny has then
Immigrated to America, where he received the prestigious Fogarty Fellowship from the National Institutes of Health.
Within the period of his fellowship in Leonard Neckers’ laboratory at the National
Cancer Institute (NCI), he was a co-author of 18 publications on
Diverse biomedical themes, like targeting
HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II
Trial paper.
 
After authoring seven papers during a brief yet productive
Senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania,
Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they
Published 26 papers. Moreover, Dr. Misha Blagosklonny published a
Lot of experimental research papers and theoretical papers as sole
Writer. Those sole-author papers
Highlighted two important topics.
The first of these explained selectively killing cancer
Cells with deregulated cell cycle or drug resistance by
Confirming their resistance. The results and underlying
Concept were so revolutionary that they were inadequately cited by
Other scientists as “reversal of resistance, ” even though the publication was
Named, “Exploiting of drug resistance instead of its reversal. ” One big
Supporter of this concept was the world-famous scientist Arthur Pardee, with whom Dr.
Blagosklonny co-authored a joint article in 2001.
 
The second theme throughout Dr. Blagosklonny’s sole-author works
Is a research methodology to create knowledge by
Bringing a few facts together from seemingly irrelevant fields.
This results in new concepts containing testable predictions, which in
Turn can be “tested” by analyzing the literature further. Once again, the
Concept was co-authored by Arthur Pardee in a 2002 article in Nature. The
First success of the new research method was the description of the feedback
Regulation of p53, as confirmed by the discovery of mdm2/p53 loop; and the
Explanation why mutant p53 is always overexpressed, published in 1997. The most
Noticeable outcome revealed by Dr.
Blagosklonny’s research methods is the hyperfunction (or quasi-programmed)
Theory of aging and the revelation of rapamycin as an exclusively well-tolerated
Anti-aging medication, published in 2006. As mentioned in Scientific American,
Michael Hall, who discovered mTOR in 1991, gives Dr. Blagosklonny credit for
“connecting dots that others do not even see. ”
 
In 2002, Dr. Blagosklonny became associate professor of medicine at New York Medical College.
He decided to accept responsibilities as a senior scientist at Ordway
Research Institute in Albany, New York, in 2005, before receiving another
Position at Roswell Park Cancer Institute as professor of oncology in 2009.
 
Since joining Roswell Park Comprehensive Cancer Center in 2009, Dr. Blagosklonny
Has studied the prevention of cancer (an age-related disease) by
Preventing body aging — in other words, “preventing cancer
Via remainng young. ” His lab closely collaborated with
Andrei Gudkov’s and conducted research on the suppression of
Cellular senescence, namely suppression of cellular conversion from healthy quiescence to
Permanent senescence. This led to the discovery of extra anti-aging
Drugs beyond rapamycin. The cell culture studies were
Accompanied by studies in mice, including a few models like
Normal and aging mice, p53-deficient mice, and mice on a high-fat diet.
 
Dr. Misha Blagosklonny has also published extensively on the prevention of cellular
Senescence by rapamycin as well as other mTOR inhibitors, life
Extension and cancer cure in mice, and combinations of anti-
Aging medicines to be taken by humans. A
Rapamycin-based combination of seven clinically available medicines has
Been named the “Koschei Formula” and is now utilized for the treatment of aging in patients
At the Alan Green Clinic in Little Neck, New York.

https://www.crunchbase.com/person/mikhail-blagosklonny#section-overview
https://sbirsource.com/sbir/people/43257-misha-blagosklonny
https://tandfonline.com/doi/abs/10.4161/cbt.8.9.8899